TAKEDA PHARMA - Dusseldorf Stock Exchang
TAKEDA PHARMA - Dusseldorf Stock Exchang operates in Diversified Metals & Mining.
TAKEDA PHARMA - Dusseldorf Stock Exchang (TKD) - Total Liabilities
Latest total liabilities as of September 2024: €7.65 Trillion EUR
Based on the latest financial reports, TAKEDA PHARMA - Dusseldorf Stock Exchang (TKD) has total liabilities worth €7.65 Trillion EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TAKEDA PHARMA - Dusseldorf Stock Exchang - Total Liabilities Trend (2017–2024)
This chart illustrates how TAKEDA PHARMA - Dusseldorf Stock Exchang's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TAKEDA PHARMA - Dusseldorf Stock Exchang Competitors by Total Liabilities
The table below lists competitors of TAKEDA PHARMA - Dusseldorf Stock Exchang ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strikewell Energy Corp
V:SKK
|
Canada | CA$28.37 Million |
|
Randall & Quilter Investment Holdings Ltd
PINK:RQIHF
|
USA | $5.65 Billion |
|
NKSJ HOLDINGS
MU:ANK
|
Germany | €11.96 Trillion |
|
Österreichische Post AG
BE:O3P
|
Germany | €5.28 Billion |
|
Pluribus Technologies Corp
V:PLRB
|
Canada | CA$39.04 Million |
|
VOLVO -B-
MU:VOL1
|
Germany | €490.02 Billion |
|
HUHTAMAKI (HUKI.SG)
STU:HUKI
|
Germany | €2.87 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down TAKEDA PHARMA - Dusseldorf Stock Exchang's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TAKEDA PHARMA - Dusseldorf Stock Exchang's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TAKEDA PHARMA - Dusseldorf Stock Exchang (2017–2024)
The table below shows the annual total liabilities of TAKEDA PHARMA - Dusseldorf Stock Exchang from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-03-31 | €7.83 Trillion | +3.05% |
| 2023-03-31 | €7.60 Trillion | +1.45% |
| 2022-03-31 | €7.49 Trillion | -3.11% |
| 2021-03-31 | €7.74 Trillion | -4.43% |
| 2020-03-31 | €8.09 Trillion | -7.06% |
| 2019-03-31 | €8.71 Trillion | +316.87% |
| 2018-03-31 | €2.09 Trillion | -13.20% |
| 2017-03-31 | €2.41 Trillion | -- |